CTRL Therapeutics is thrilled to announce that we have successfully raised $9,140,000 in our latest funding round, a significant step forward in our mission to revolutionize the cell therapy landscape. With this substantial investment, we are fully equipped to propel our development of cutting-edge autologous cell therapies specifically focused on patients battling solid tumors. At CTRL Therapeutics, we believe in the transformative power of personalized medicine, and with this funding, we aim to dedicate our resources to bringing innovative solutions to those who need them most. Our company's culture is anchored in collaboration, transparency, integrity, and an unwavering commitment to excellence; values that we are instilling in every aspect of our operations as we seek out passionate individuals to join us on this journey. The funds will be instrumental in advancing our research and development initiatives, enhancing our laboratory capabilities, and scaling our production processes. Furthermore, this new financial backing allows us to expand our team of talented professionals, whose expertise will be critical to the success of our therapies. As we move forward, we remain steadfast in our mission to change the lives of cancer patients and redefine the treatment landscape for solid tumors with our innovative cell therapies. This is just the beginning, and we are excited about the future as we embark on this meaningful endeavor together.








